Skip to main content

National Institute of Allergy and Infectious Diseases — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

64
Companies
$149.3M
Total invested
$2.8M
Avg. check
21
Industries
Biotechnology 21Health Care 10Medical 7Pharmaceutical 6Therapeutics 5Biopharma 5+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 64
Lactiga
September 2025

Lactiga is a biotherapeutics company advancing its patented biologics to transform the anti-infective sector and protect vulnerable patients

Biotechnology · PrincetonGrant
Sunflower Therapeutics
September 2025

Sunflower Therapeutics is a biotech company that delivers next-generation protein manufacturing solutions.

Biotechnology · Hingham$300K Grant
Omniose
September 2023

Omniose is an early stage biotechnological company.

Biotechnology · St Louis$3.0M Grant
Resvita Bio
September 2024

Resvita Bio develops and manufactures engineered probiotics for use in treatment if skin related diseases including cancer.

Biotechnology · Berkeley$2.0M Grant
Scanogen
September 2025

Scanogen is a molecular diagnostic company.

Biotechnology · Windsor Mill$2.9M Grant
Ceramedix Holding
August 2023

Ceramedix Holding is a biotherapeutics company that develops antibody-based drugs with the aim of addressing novel diseases.

Biopharma · New York$3.0M Grant
Exavir Therapeutics
August 2023

Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.

Biotechnology · San Francisco$3.0M Grant
Institute for Bioscience and Biotechnology Research
August 2022

IBBR is leverages state-of-art integrative methods for bioanalytical, biophysical and structural characterization of biomolecules.

Biotechnology · Rockville$6.9M Grant
Acenxion Biosystems
August 2024

Acenxion Biosystems is a privately funded company developing automated medical diagnostic systems for precision medicine.

Biotechnology · Lawrence$1.1M Seed
Aldatu Biosciences
August 2024

Aldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases.

Biotechnology · Watertown$3.0M Grant
Melax Technologies
August 2022

Melax Technologies specializes in machine learning, software, domain, natural language processing and medical coding services.

Artificial Intelligence (AI) · Houston$300K Grant
Intact Genomics
July 2022

Intact Genomics provides high-quality life science products and large DNA fragment cloning related services

Biopharma · Creve Coeur$2.9M Grant
Clairyon
June 2024

Clairyon is a healthcare technology company that specializes in outpatient monitoring, predictive analytics, and quality reporting services.

Artificial Intelligence (AI) · San Diego$1.0M Grant
MiNK Therapeutics
June 2025

MiNK Therapeutics is a biopharmaceutical company developing allogeneic iNKT cell therapies and immune technologies for treatment.

Biopharma · New YorkGrant
Sapience Therapeutics
May 2023

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs

Biotechnology · Scarsdale$2.0M Grant
Calder Biosciences
May 2025

Calder Biosciences is a groundbreaking biotechnology and molecular engineering firm developing next generation subunit vaccines

Biopharma · New YorkSeed
Versatope Therapeutics
May 2025

Versatope is an immuno-therapeutic company that uses a biotechnology platform to delivery immunity.

Biotechnology · Lowell$200K Grant
Truly Technologies
May 2023

Truly Technologies develops biospecimen processing technologies for diagnostic, therapeutic and life science research applications.

Biotechnology · Seattle$273K Grant
ReAlta Life Sciences
April 2026

ReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases.

Biotechnology · Norfolk$40.0M Undisclosed
TFF Pharmaceuticals
April 2024

TFF Pharmaceuticals is a clinical-stage biopharmaceutical company that develops drug products.

Biopharma · Austin$4.8M Post-IPO Equity
Phase Genomics
March 2024

Phase Genomics develops a biotechnology platform for new discoveries in agriculture, human health, and industrial biology industries.

Bioinformatics · Seattle$1.5M Grant
Blacksmith Medicines
February 2024

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.

Biotechnology · San Diego$3.3M Grant
ILiAD Biotechnologies
February 2026

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

Biotechnology · New York$115.0M Series D
Osivax
March 2025

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

Biotechnology · Lyon$10.5M Series B

Where National Institute of Allergy and Infectious Diseases invests

Biotechnology21
Health Care10
Medical7
Pharmaceutical6
Therapeutics5
Biopharma5

About National Institute of Allergy and Infectious Diseases's portfolio

How many companies has National Institute of Allergy and Infectious Diseases invested in?

National Institute of Allergy and Infectious Diseases has invested in 64 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does National Institute of Allergy and Infectious Diseases invest in?

National Institute of Allergy and Infectious Diseases's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 21 different industry categories.

What is National Institute of Allergy and Infectious Diseases's largest investment?

Among tracked funding rounds, ILiAD Biotechnologies received $115.0M in a Series D round. National Institute of Allergy and Infectious Diseases's total known invested capital is $149.3M.

What is the average investment size for National Institute of Allergy and Infectious Diseases?

National Institute of Allergy and Infectious Diseases's average investment size is $2.8M across its portfolio of 64 companies.

What are National Institute of Allergy and Infectious Diseases's most recent investments?

Recent National Institute of Allergy and Infectious Diseases portfolio additions include Lactiga, Sunflower Therapeutics, Omniose, Resvita Bio, Scanogen. These companies were founded in 2020 or later.

Reach the founders behind these 64 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →